Nuijens A, Oei A, Franken N, Rasch C, Stalpers L
Curr Oncol. 2025; 32(1).
PMID: 39851963
PMC: 11763857.
DOI: 10.3390/curroncol32010047.
Naderi E, Crijns A, Steenbakkers R, van den Hoek J, Boezen H, Alizadeh B
J Transl Med. 2021; 19(1):481.
PMID: 34838041
PMC: 8626989.
DOI: 10.1186/s12967-021-03145-1.
Wang X, Li B
Front Genet. 2021; 12:624820.
PMID: 33643386
PMC: 7902873.
DOI: 10.3389/fgene.2021.624820.
Capobianco E, Deng J
Cancers (Basel). 2020; 12(9).
PMID: 32872466
PMC: 7563283.
DOI: 10.3390/cancers12092453.
Kang J, Coates J, Strawderman R, Rosenstein B, Kerns S
Med Phys. 2020; 47(5):e203-e217.
PMID: 32418335
PMC: 8725063.
DOI: 10.1002/mp.13751.
Individual response of humans to ionising radiation: governing factors and importance for radiological protection.
Applegate K, Ruhm W, Wojcik A, Bourguignon M, Brenner A, Hamasaki K
Radiat Environ Biophys. 2020; 59(2):185-209.
PMID: 32146555
DOI: 10.1007/s00411-020-00837-y.
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.
Kalbasi A, Kamrava M, Chu F, Telesca D, van Dams R, Yang Y
Clin Cancer Res. 2020; 26(8):1829-1836.
PMID: 32054730
PMC: 7189949.
DOI: 10.1158/1078-0432.CCR-19-3524.
Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.
Morton L, Ricks-Santi L, West C, Rosenstein B
Int J Part Ther. 2018; 5(1):103-113.
PMID: 30505881
PMC: 6261418.
DOI: 10.14338/IJPT-18-00009.1.
Developing Predictive or Prognostic Biomarkers for Charged Particle Radiotherapy.
Story M, Wang J
Int J Part Ther. 2018; 5(1):94-102.
PMID: 30393751
PMC: 6214484.
DOI: 10.14338/IJPT-18-00027.1.
Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology.
Matuszak M, Fuller C, Yock T, Hess C, McNutt T, Jolly S
Med Phys. 2018; 45(10):e811-e819.
PMID: 30229946
PMC: 6679351.
DOI: 10.1002/mp.13136.
Genomics, bio specimens, and other biological data: Current status and future directions.
Rosenstein B, Rao A, Moran J, Spratt D, Mendonca M, Al-Lazikani B
Med Phys. 2018; 45(10):e829-e833.
PMID: 30226926
PMC: 6214357.
DOI: 10.1002/mp.12912.
Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Grossberg A, Lei X, Xu T, Shaitelman S, Hoffman K, Bloom E
JAMA Oncol. 2018; 4(12):1751-1757.
PMID: 30027292
PMC: 6248087.
DOI: 10.1001/jamaoncol.2018.2583.
Radiation biology and oncology in the genomic era.
Kerns S, Chuang K, Hall W, Werner Z, Chen Y, Ostrer H
Br J Radiol. 2018; 91(1091):20170949.
PMID: 29888979
PMC: 6475928.
DOI: 10.1259/bjr.20170949.
Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.
Rosenstein B
Semin Radiat Oncol. 2017; 27(4):300-309.
PMID: 28865512
PMC: 5657449.
DOI: 10.1016/j.semradonc.2017.04.005.
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
Kerns S, Dorling L, Fachal L, Bentzen S, Pharoah P, Barnes D
EBioMedicine. 2016; 10:150-63.
PMID: 27515689
PMC: 5036513.
DOI: 10.1016/j.ebiom.2016.07.022.
Identifying molecular genetic features and oncogenic pathways of clear cell renal cell carcinoma through the anatomical (PADUA) scoring system.
Zhu H, Chen H, Lin Z, Shi G, Lin X, Wu Z
Oncotarget. 2016; 7(9):10006-14.
PMID: 26848523
PMC: 4891099.
DOI: 10.18632/oncotarget.7129.
The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention.
Kerns S, Kundu S, Oh J, Singhal S, Janelsins M, Travis L
Semin Radiat Oncol. 2015; 25(4):281-91.
PMID: 26384276
PMC: 4576690.
DOI: 10.1016/j.semradonc.2015.05.006.
The current progress and future prospects of personalized radiogenomic cancer study.
Liu J, Shen W, Shih T, Tsai C, Chang W, Cho D
Biomedicine (Taipei). 2015; 5(1):2.
PMID: 25705582
PMC: 4328115.
DOI: 10.7603/s40681-015-0002-0.
Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.
Kerns S, Ostrer H, Rosenstein B
Cancer Discov. 2014; 4(2):155-65.
PMID: 24441285
PMC: 3946319.
DOI: 10.1158/2159-8290.CD-13-0197.
HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer.
Xu T, Wei Q, Lopez Guerra J, Wang L, Liu Z, Gomez D
Int J Radiat Oncol Biol Phys. 2012; 84(2):e229-35.
PMID: 22608953
PMC: 3426644.
DOI: 10.1016/j.ijrobp.2012.03.032.
